AGENUS INC

AGEN, which trades under the ticker AGEN, is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. Its pipeline includes investigational agents designed to activate the immune system against tumors. The company's work spans multiple programs targeting different cancer types. Because it is clinical-stage, its prospects are closely tied to the progress of its drug candidates through research and regulatory review. For the latest description of its operations, refer to the company profile data shown on this page.

The current price of AGEN stock is displayed at the top of this page and updates with market activity. Because stock prices change throughout the trading day, the most accurate figure is the latest quote shown here. You can also review the day's open, high, low, and previous close alongside the live price. For historical closing prices, consult the price history section on this page.

AGEN is a small-cap biotechnology stock, a category that often experiences larger price swings than more established companies. Volatility can be influenced by clinical trial updates, regulatory news, financing activities, and broader market sentiment toward biotech. The 52-week range and recent price movement shown on this page provide context for how widely the shares have traded. Reviewing historical price data can help investors understand the stock's typical trading range, but it does not predict future moves.

Because AGEN is a clinical-stage biotech company, traditional valuation metrics like the price-to-earnings ratio may not be meaningful if the company is not yet profitable. Investors often consider cash position, research and development spending, pipeline progress, and potential market opportunities for its drug candidates. Price-to-book or enterprise value relative to cash can also be referenced. The valuation data displayed on this page, such as market capitalization and any available ratios, provides a starting point for further analysis.

AGEN stock may be available for trading in pre-market and after-hours sessions through certain brokers, though liquidity and price spreads can be less favorable than during regular market hours. Extended-hours trading is not available on all platforms, and orders may not execute if there is insufficient volume. The regular market session for U.S. stocks is typically 9:30 a.m. to 4:00 p.m. Eastern Time. Check with your broker for specific extended-hours availability.

As a clinical-stage biotechnology company, AGEN faces risks related to drug development, including the possibility that its product candidates fail in clinical trials or do not receive regulatory approval. The company may need additional capital to fund research and operations, which could involve issuing new shares and diluting existing holders. Other risks include competition, reliance on key personnel, and changes in healthcare policy or reimbursement. The risk factors disclosed in the company's SEC filings provide a more detailed discussion.